Abstract
In this chapter we summarize the clinical and experimental data which indicate that bacteria, especially from the endogenous microflora, play a role in the pathogenesis of Crohn's disease, ulcerative colitis and pouchitis. We review the clinical trials, focusing on randomized controlled trials which used antibiotics or probiotics to treat situations of IBD or prevent recurrence, and we discuss the future of this approach.
MeSH terms
-
Anti-Bacterial Agents / pharmacology
-
Anti-Bacterial Agents / therapeutic use
-
Antitubercular Agents / therapeutic use*
-
Ciprofloxacin / therapeutic use*
-
Enterobacteriaceae / drug effects*
-
Humans
-
Inflammatory Bowel Diseases / drug therapy*
-
Inflammatory Bowel Diseases / microbiology*
-
Inflammatory Bowel Diseases / physiopathology
-
Nitroimidazoles / therapeutic use*
-
Pouchitis / drug therapy
-
Pouchitis / microbiology
-
Pouchitis / physiopathology
-
Probiotics / pharmacology*
-
Probiotics / therapeutic use
-
Randomized Controlled Trials as Topic
-
Secondary Prevention
Substances
-
Anti-Bacterial Agents
-
Antitubercular Agents
-
Nitroimidazoles
-
Ciprofloxacin